CN Patent

CN109528721B — 联合治疗

Assigned to Alcon Inc · Expires 2021-10-01 · 5y expired

What this patent protects

本发明涉及联合治疗。本文描述了用于治疗青光眼和/或降低眼内压的化合物和组合物。组合物可包含异喹啉化合物和前列腺素或前列腺素类似物。本文所述化合物包括异喹啉化合物与前列腺素或前列腺素类似物共价连接的那些和异喹啉化合物和前列腺素游离酸一起形成盐的那些。

USPTO Abstract

本发明涉及联合治疗。本文描述了用于治疗青光眼和/或降低眼内压的化合物和组合物。组合物可包含异喹啉化合物和前列腺素或前列腺素类似物。本文所述化合物包括异喹啉化合物与前列腺素或前列腺素类似物共价连接的那些和异喹啉化合物和前列腺素游离酸一起形成盐的那些。

Drugs covered by this patent

Patent Metadata

Patent number
CN109528721B
Jurisdiction
CN
Classification
—
Expires
2021-10-01
Drug substance claim
No
Drug product claim
No
Assignee
Alcon Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.